Jupiter Topco LLC Takes $266.63 Million Position in Dyne Therapeutics, Inc. $DYN

Jupiter Topco LLC acquired a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,997,738 shares of the company’s stock, valued at approximately $266,634,000. Jupiter Topco LLC owned approximately 6.42% of Dyne Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares in the last quarter. BlackRock Inc. acquired a new stake in Dyne Therapeutics in the 2nd quarter valued at approximately $275,500,000. Orbis Allan Gray Ltd bought a new stake in Dyne Therapeutics in the 4th quarter valued at approximately $93,926,000. Adage Capital Partners GP L.L.C. bought a new stake in Dyne Therapeutics in the 2nd quarter valued at approximately $30,378,000. Finally, Perceptive Advisors LLC boosted its position in Dyne Therapeutics by 543.7% during the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after acquiring an additional 2,938,500 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Up 1.3%

Shares of DYN opened at $26.34 on Wednesday. The firm has a market cap of $4.92 billion, a P/E ratio of -7.91 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The firm’s 50-day simple moving average is $23.99 and its 200 day simple moving average is $19.89.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DYN. Morgan Stanley decreased their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Royal Bank Of Canada lifted their target price on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Cantor Fitzgerald started coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating for the company. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 15th. Finally, TD Cowen began coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Insider Activity at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 2,160,516 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares in the company, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 4,139,196 shares of company stock valued at $99,449,852. 9.46% of the stock is currently owned by insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.